ストックスクリーナーアプリを入手
0.00
100.00%
-0.037
前日終値:
$0.037
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-92.59%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
NKGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nkgen Biotech Inc (NKGN) 最新ニュース
NKGen Biotech Secures New Promissory Note Financing - TipRanks
NKGen Biotech issues statement on NKGen Korea board appointments - MSN
Financial Review: Alpha Cognition (OTC:ACOGF) vs. NKGen Biotech (NYSE:NKGN) - Defense World
Analyzing Genocea Biosciences (NASDAQ:GNCA) and NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech, Inc. Issues Statement on Recent Board - GlobeNewswire
NKGen Biotech (OTC: NKGN) backs new NKGen Korea board for Asia NK cell growth - Stock Titan
Is NKGen Biotech, Inc. technically bullish or bearish? - Markets Mojo
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKMAX CO., Ltd. has Changed its Name to NKGen Korea - marketscreener.com
Sorrento Therapeutics (NASDAQ:SRNE) versus NKGen Biotech (NYSE:NKGN) Head-To-Head Review - Defense World
Sorrento Therapeutics (OTCMKTS:SRNEQ) & NKGen Biotech (NYSE:NKGN) Head-To-Head Review - Defense World
Reviewing NKGen Biotech (NYSE:NKGN) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Total debt per share of NKGen Biotech Inc. – OTC:NKGN - TradingView
Revenue per share of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech, Inc. (NKGN) Eps Diluted (Quarterly) - Zacks Investment Research
Nkgen Biotech’s Promising Alzheimer’s Study: A Potential Game-Changer? - TipRanks
NKGen Biotech Secures $2.5M in Stock Purchase Agreement - MSN
NKGen Biotech, Inc. (NKGNW) Stock Price, News, Quote & History - Yahoo
NKGen Biotech, Inc. (NKGNW) stock price, news, quote and history - Yahoo
NKGen Biotech provides clarification on quotation display, trading status - MSN
NKGen Biotech, Inc. (NKGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
NKGen Biotech, Inc. (NKGN) Company Profile & Facts - Yahoo
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - The Manila Times
Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan
NKGen Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
NKGen Biotech, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
NKGen Biotech to Present on the Use of Troculeucel for - GlobeNewswire
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - The Manila Times
NKGen to Present Troculeucel for Alzheimer's at WCN Oct 15 | NKGN Stock News - Stock Titan
NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World
NKGen Biotech Announces Consulting Agreement with Dr. Kim - MSN
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors - Investing.com Nigeria
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors By Investing.com - Investing.com South Africa
NKGen Biotech CEO to present NK cell therapy data at China forum - Investing.com Australia
Breakthrough NK Cell Therapy for Neurodegenerative Diseases: NKGen Biotech Presents Latest Clinical Data - Stock Titan
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum - Yahoo Finance
LadRx (OTCMKTS:CYTR) & NKGen Biotech (NYSE:NKGN) Head-To-Head Analysis - Defense World
NKGen Biotech announces completion of NKMax acquisition - MSN
NKGen Biotech Acquires Majority Stake in NKMax - TipRanks
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - The Manila Times
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire
$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire
Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN
NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World
NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire
Nkgen Biotech Inc (NKGN) 財務データ
Nkgen Biotech Inc (NKGN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):